AroCell AB: TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium

AroCell AB (publ) announces today that an abstract submitted Kiran Kumar Jagarlamudi et al entitled "The AroCell TK 210 ELISA provides new information concerning the mechanism of anti-cancer drugs by determining the TK1 protein levels in cultured cells in vitro" was accepted by the NCRI for presentation at their annual meeting in Liverpool, November 5-8, 2017.

The purpose of this study was to evaluate the capacity of TK 210 ELISA to measure TK1 levels in tumor cell culture models, using CEM lymphoblastic cells and Doxorubicin, which is an effective anti-neoplastic drug for both hematological and solid malignancies, and a commonly used chemotherapy drug. The conclusion in the study is that use of AroCell TK 210 ELISA provides opportunities for in-vitro studies of old and new anti-cancer drugs, targeting cell proliferation, which may assist in the development of new therapeutic agents.

"We are delighted over the results in this study and it is another piece of evidence that TK 210 ELISA will have a very broad applicability also in early stage drug development" states Jan Stålemark, CEO. "Controlling and/or inhibiting cell proliferation is an important parameter in early drug development and thus in the selection of drug candidates for cancer therapy. However, there are few cell-proliferation biomarkers which are suitable for large-scale use in in-vitro studies. This present work shows that TK1 levels in-vitro can be used to gain information on the effects of anti-cancer agents with tumor derived model cell lines. Furthermore, measuring the serum TK1 levels in patients with the TK 210 ELISA has been shown to provide clinically valuable information in a range of malignancies. This means that the assay of TK1 with the AroCell TK 210 ELISA test has the potential to enable routine application to drug discovery studies and in clinical trials. This potential is reinforced by another recent abstract on cell culture entitled Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development" says Jan Stålemark.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 11.30 CET on 22 September 2017.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see Redeye AB is AroCell:s Certified Adviser.

AroCell press release Sept 22, 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AroCell AB via Globenewswire